Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of
RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
Phase:
Phase 2
Details
Lead Sponsor:
Revance Therapeutics, Inc.
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA